Clinical trial NCT06937190: Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
Official title: Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Anaerobic Performance
Sports Nutrition
Exercise Recovery
Muscle Fatigue
Creatine Supplementation
Recreational Physical Activity
Female Athletes
Keywords: Creatine Monohydrate
Pre-Sleep Supplementation
Anaerobic Power
Wingate Test
Muscle Damage Markers
Creatine Kinase (CK)
Lactate Dehydrogenase (LDH)
Female Exercise Performance
Nutritional Ergogenic Aid
Resistance Training
Recovery Enhancement
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2025-04-22
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are randomly assigned to one of two groups: a creatine supplementation group or a placebo group, and they remain in that group for the duration of the trial.
Primary purpose: TREATMENT

Brief summary: This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.


Eligibility criteria: Inclusion Criteria:

Female, aged 18 to 25 years

Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)

Regular menstrual cycles (used for scheduling purposes)

Able and willing to provide informed consent

Agreement to maintain normal diet and training routines throughout the study

Exclusion Criteria:

History of musculoskeletal injury affecting lower or upper limbs within the past 6 months

Known allergy or intolerance to creatine or maltodextrin

Use of performance-enhancing substances or supplements within the last 30 days

Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period

Current use of anti-inflammatory medication

Pregnancy or breastfeeding

Inability to comply with study protocol or scheduled assessments

Primary outcomes:
measure: Average Power Output (Watts) - 30-Second Wingate Test
timeFrame: Baseline and post-intervention (Day 0 and Day 7)
Secondary outcomes:
measure: Peak Power Output (Watts) - Wingate Test
timeFrame: Baseline and post-intervention (Day 0 and Day 7)
measure: Fatigue Index (%) - Wingate Test
timeFrame: Baseline and post-intervention (Day 0 and Day 7)
measure: Serum Creatine Kinase (CK) Activity
timeFrame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)
measure: Serum Lactate Dehydrogenase (LDH) Activity
timeFrame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)
Other outcomes:
Locations:
city: Shabestar
country: Iran, Islamic Republic of
facility: Islamic Azad University, Shabestar Branch
state: East Azerbaijan
Study officials:
References: